Completed PHASE1 INTERVENTIONAL 7-arm NCT02051387

Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study (CBD-IS)

Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study With Approved Antipsychotics in Vivo

Sponsor: Central Institute of Mental Health, Mannheim

Conditions Schizophrenia

Interventions Amisulpride Cannabidiol Cannabidiol CR Olanzapine Placebo Quetiapine Risperidone

Updated 6 times since 2017 Last updated: Mar 7, 2018 Started: Jan 31, 2013 Primary completion: Aug 31, 2017 Completion: Aug 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02051387, this PHASE1 trial focuses on Schizophrenia and remains completed. Sponsored by Central Institute of Mental Health, Mannheim, it has been updated 6 times since 2013, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Mar 2018 — Jun 2018 [monthly]

Completed PHASE1

Status: Recruiting → Completed

▶ Show 1 earlier version

Jan 2017 — Mar 2018 [monthly]

Recruiting PHASE1

First recorded

Jan 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Central Institute of Mental Health, Mannheim
University of Cologne

Data source: Central Institute of Mental Health, Mannheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cologne, Germany
• Mannheim, Germany